Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07529717) titled 'First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer' on April 8.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: AstraZeneca
Condition:
Metastatic Prostate Cancer
Intervention:
Drug: AZD8359
Drug: AZD8359
Drug: AZD8359
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: April 9, 2026
Target Sample Size: 42
Countries of Recruitment:
United States
Australia
South Korea
Australia
South Korea
United States...